LCTX

LCTX Operating Expenses

$39.49MTTM · USD

Period ending:

LCTX FY Operating ExpensesUSD
LCTX FY Operating Expenses1992-06-30: $400.00K1993-06-30: $800.00K1994-06-30: $1.70M1995-06-30: $2.60M1996-06-30: $2.10M1998-06-30: $3.30M1998-12-31: $2.40M1999-12-31: $6.86M2000-12-31: $5.22M2001-12-31: $3.65M2002-12-31: $2.42M2003-12-31: $2.25M2004-12-31: $2.66M2005-12-31: $2.92M2006-12-31: $2.91M2007-12-31: $2.27M2008-12-31: $4.33M2009-12-31: $5.45M2010-12-31: $13.53M2011-12-31: $23.04M2012-12-31: $26.26M2013-12-31: $40.59M2014-12-31: $51.79M2015-12-31: $67.24M2016-12-31: $60.86M2017-12-31: $42.28M2018-12-31: $42.11M2019-12-31: $39.94M2020-12-31: $26.84M2021-12-31: $51.68M2022-12-31: $36.50M2023-12-31: $33.01M2024-12-31: $30.64M2025-12-31: $35.49M$67.24M$0.00
1992-06-302025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

LCTX operating expenses history

Expenses from normal business operations (SG&A, R&D, etc.). The available annual fiscal periods series contains 34 observations from Jun 30, 1992 to Dec 31, 2025.

Lineage Cell Therapeutics, Inc. Common Stock Operating Expenses — Annual fiscal periods (USD)
Period endingOperating Expenses (USD)
35,490,000
30,643,000
33,007,000
36,495,000
51,681,000
26,835,000
39,942,000
42,109,000
42,280,000
60,861,000
67,236,000
51,791,894
40,594,768
26,259,275
23,041,193
13,532,433
5,445,434
4,326,424
2,268,494
2,913,879
2,921,611
2,657,151
2,246,250
2,421,649
3,646,510
5,218,230
6,856,751
2,400,000
3,300,000
2,100,000
2,600,000
1,700,000
800,000
400,000

Compare operating expenses

All LCTX financial metrics · LCTX stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.